Celltrion, Inc.

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2022	KRW	USD
Revenue	2,283.96B	1,767.63M
Gross Profit	991,885.35M	767.65M
Operating income	647,199.86M	500.88M
Income before tax	619,117.32M	479.15M
Net income	526,616.03M	407.56M
EBITDA	822,487.46M	636.55M
Diluted EPS	3,680.88	2.84
Dividends Per Share	360.57	0.27
Total Assets	5,891.65B	4,659.27M
Total liabilities	1,617.44B	1,279.12M
Total equity	4,139.36B	3,273.51M
Operating cash flow	-8,939.24M	-6.91M
	Currency in KRW	Currency in USD

Historical Data

KRW | USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022
Revenue	982,074.95M	1,128.45B	1,849.11B	1,893.40B	2,283.96B
Gross Profit	544,684.88M	623,118.64M	1,016.64B	1,050.66B	991,885.35M
Operating income	322,728.11M	381,535.86M	718,579.05M	744,162.54M	647,199.86M
Income before tax	302,159.30M	382,510.47M	654,561.59M	742,209.04M	619,117.32M
Net income	245,755.01M	301,030.34M	517,759.53M	569,488.02M	526,616.03M
EBITDA	447,554.58M	535,255.48M	892,388.45M	958,322.27M	822,487.46M
Diluted EPS	1,652.66	2,074.44	3,560.57	3,981.47	3,680.88
Dividends Per Share	0	0	0	707.01	360.57
Total Assets	3,590.82B	3,859.64B	5,020.12B	5,674.12B	5,891.65B
Total liabilities	992,561.59M	983,733.41M	1,589.54B	1,620.74B	1,617.44B
Total equity	2,486.50B	2,760.10B	3,307.67B	3,917.23B	4,139.36B
Operating cash flow	354,768.82M	468,031.66M	342,017.88M	901,686.05M	-8,939.24M

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022
Revenue	892.37M	967.65M	1,567.19M	1,653.39M	1,767.63M
Gross Profit	494.93M	534.32M	861.64M	917.48M	767.65M
Operating income	293.25M	327.16M	609.02M	649.83M	500.88M
Income before tax	274.56M	328.00M	554.76M	648.12M	479.15M
Net income	223.30M	258.13M	438.82M	497.30M	407.56M
EBITDA	406.67M	458.98M	756.33M	836.84M	636.55M
Diluted EPS	1.50	1.77	3.01	3.47	2.84
Dividends Per Share	0	0	0	0.61	0.27
Total Assets	3,218.15M	3,337.49M	4,621.30M	4,773.18M	4,659.27M
Total liabilities	889.55M	850.64M	1,463.26M	1,363.40M	1,279.12M
Total equity	2,228.44M	2,386.70M	3,044.90M	3,295.25M	3,273.51M
Operating cash flow	322.36M	401.33M	289.87M	787.38M	-6.91M

Valuation Measures

Dec 2022
PER	43.53
ROA	9.10%
ROE	13.07%
Operating margin	28.33%
Profit margin	23.05%

Management

Chief Executive Officer & Director: Wu-Sung Ki
Finance Director: Ho-Seop Lee
Head-Legal & Compliance Support: Sung-Han Lee
Vice President: Sang-Joon Lee
Vice President: Jung-Won Yoon

Shareholders

SEO JUNG-JIN (22.1%)
National Pension Service of Korea (7.4%)
Temasek Holdings Pte Ltd. (Investment Management) (4.1%)
Celltrion, Inc. (2.6%)
The Vanguard Group, Inc. (2.5%)
BlackRock Fund Advisors (1.6%)
Norges Bank Investment Management (1.1%)
Mirae Asset Global Investments Co., Ltd. (1.0%)
Samsung Asset Management Co., Ltd. (0.7%)
BlackRock Advisors (UK) Ltd. (0.5%)

Contact Details

Website:http://www.celltrion.com
Address: 23 Academy-ro, Yeonsu-gu, Inchon, 22014, South Korea
Phone: +82.32.850.5000

Related Companies

Celltrion Asia Pacific Pte Ltd.
Celltrion Group Hong Kong Ltd.
Celltrion Biopharma Ltd.
Celltrion Global Safety Data Center, Inc.
Celltrion Europe Ltd.
Vcell Healthcare Ltd.
Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
Celltrion Inc. Employee Stock Ownership ASSN.
Celltrion Pharm Inc.

Competitors

SAMSUNG BIOLOGICS Co., Ltd.
Hikma Pharmaceuticals Plc
Novartis AG
Teva Pharmaceutical Industries Limited
Amgen Inc.
Pfizer Inc.
AstraZeneca PLC
Bio-Thera Solutions, Ltd. Class A
Gilead Sciences, Inc.
Fresenius SE & Co. KGaA
Sanofi
Coherus BioSciences, Inc.
Glenmark Pharmaceuticals Limited
GSK plc
LG Chem Ltd.
Otsuka Holdings Co., Ltd.
Sam Chun Dang Pharm. Co., Ltd.
Chemical Works of Gedeon Richter Plc
Viatris, Inc.
Formycon AG
JW Pharmaceutical Corporation
Reyon Pharmaceutical Co., Ltd.
PharmGen Science, Inc.
EPIRUS Biopharmaceuticals, Inc.
EirGenix Inc
PharmAbcine Inc.
Bukwang Pharmaceutical Co., Ltd.
ALTEOGEN Inc.
Greenwich LifeSciences, Inc.
Prestige Biologics Co., Ltd.

Last Updated on 21 Sep, 2023